TOFANE-GLOBAL
9.1.2023 18:01:40 CET | Business Wire | Press release
Tofane Global (TOFANE), the leading international communications solutions group, announces today the acquisition of DIMOCO Messaging, a leading global SMS aggregator based in Liechtenstein and Austria that delivers around two billion messages per year.
Business messaging or application-to-person (A2P) has grown into a global market worth an estimated 26.5 billion USD in 2022 and is predicted to reach 38 billion USD in 2025. With only 5% of companies using SMS A2P, business adoption of messaging is still in its infancy but is starting to surge as organizations come to realize that business SMS can become a key revenue generator for mobile operators.**
With this acquisition, TOFANE’s subsidiary iBASIS significantly accelerates its growth, doubling mobile services revenues to reach 20% of the company’s total revenues.
The addition of DIMOCO Messaging enhances iBASIS’s carrier-grade network infrastructure by adding more than 100 direct connections to mobile operators worldwide, ensuring the highest standards of speed and reliability for message termination.
iBASIS geographically expands its global commercial presence with DIMOCO Messaging’s offices located in Liechtenstein, Austria, Germany, and Serbia.
The acquisition also gives direct access to the enterprise market segment where DIMOCO Messaging has an established sales force to serve large financial institutions, leveraging new SMS Application Program Interfaces for system integration, APIs for rapid onboarding, and SMS campaign deployment.
Alexandre Pébereau, CEO, iBASIS, and Founder, CEO, TOFANE:
“TOFANE established itself as the first independent leader through acquisitions in international voice. Today, we are replicating our model in the similar but high-growth Business Messaging sector to build our second pillar. By adding DIMOCO Messaging and its senior team, we are boosting our growth path to become the preferred Tier One partner for our customers in mobile services.”
Cameron Calof, Managing Director, DIMOCO Messaging:
“We are very excited to join iBASIS. The company has built a Tier One reputation as preferred partner for global voice and mobile services. We share the same entrepreneurial spirit, business ethics, and customer-centric approach, and are committed to delivering a high level of quality and reliability for messaging worldwide. We are thrilled for our employees and customers as this acquisition opens a new era of possibilities and growth. iBASIS’ expertise and capabilities are undisputed, and we look forward to continuing to respond to the industry’s fast-growing market requirements together.”
Jeantet acted as exclusive legal adviser, Mazars as finance and tax adviser, Wagram Corporate Finance as financial adviser, and Global Telco Consult – GTC as technical adviser on this acquisition.
* DACH: Deutschland (D), Austria (A), and Switzerland (CH)
** Mobilesquared, Business Messaging Overview at MEF Business Messaging, June 2022
About Tofane Global
Tofane Global (TOFANE) is the leading communications solutions group enabling operators and digital players worldwide with their core strategies, performance, and transformation. Tofane Global acquired and successfully integrated seven companies in the global communications market, becoming the first independent player and innovation enabler across international Voice, Mobile Data and SMS messaging, Internet-of-Things, and 5G. As the result of the acquisitions of Altice Europe N.V., iBASIS, SFR, MEO (former Portugal Telecom), NOS, and Simfony, Tofane Global serves 1,000+ customers worldwide across its presence in 26 countries.
About DIMOCO Messaging
Before its acquisition by Tofane Global, DIMOCO Messaging was owned by BaseTech Ventures, an investment venture that invests in early-stage FinTech, internet, and technology start-ups. DIMOCO Messaging provides high quality, reliable A2P messaging products enabling our enterprise clients to communicate to their customers on a truly global scale. We leverage our relationships with Mobile Network Operators, CPaaS and in-country partners to offer clients direct connectivity, allowing them to optimize communication with their customers and employees seamlessly. DIMOCO Messaging, with offices in Liechtenstein, Austria, Germany, and Serbia, holds an MVNO license and operates a carrier-grade messaging platform with highest quality industry standards.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230109005012/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom